WinCap Financial’s CRISPR Therapeutics CRSP Stock Holding History

WinCap Financial’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,790	Closed	-$513K	–	89
2025 Q4	$513K	Buy	9,790 +378	+4%	+$22.6K	0.35%	68
2025 Q3	$610K	Buy	9,412 +113	+1%	+$6.49K	0.42%	59
2025 Q2	$452K	Buy	9,299 +48	+0.5%	+$1.86K	0.36%	66
2025 Q1	$315K	Buy	9,251 +1,981	+27%	+$84K	0.3%	71
2024 Q4	$286K	Buy	+7,270	New	+$343K	0.29%	69

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WinCap Financial's CRSP Position: Q1 2026 in Review

WinCap Financial sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 9,790 shares — an estimated $513K sold.

WinCap Financial first reported a position in CRSP in Q4 2024 and held it in 5 quarters. The position peaked at $610K in Q3 2025. 489 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

WinCap Financial reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
WinCap Financial sold 9,790 CRISPR Therapeutics shares in Q1 2026, an estimated $513K.
WinCap Financial first reported a position in CRISPR Therapeutics in Q4 2024 and held it in 5 quarters.
WinCap Financial's CRISPR Therapeutics position peaked at $610K in Q3 2025.
489 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on WinCap Financial's 13F filing for Q1 2026, filed 9 Apr 2026.